How Effective is Temozolomide for Treating Pituitary Tumours and when Should It Be Used?

Overview

Journal Pituitary

Specialty Endocrinology

Date 2016 Sep 2

PMID 27581836

Citations 29

Authors

Carmel Halevy

Benjamin C Whitelaw

Affiliations

Soon will be listed here.

Abstract

Temozolomide (TMZ) has been shown as an effective treatment option in aggressive pituitary adenomas and carcinomas. This review analyses the published case series and demonstrates 42 % of patents show a radiological response and 27 % experience stable disease following TMZ. Prolactinomas and corticotroph tumours respond best to TMZ, showing approximately a 50 % response rate, with non-functioning tumours responding only half as frequently. Other factors that may predict the tumour's TMZ response include MGMT and MSH status, but neither is sufficiently robust to determine treatment decisions. TMZ has an accepted role in treating pituitary carcinoma and adenomas if radiation and surgery have failed to control tumour growth. To use TMZ on the basis of anticipated future aggression, as a primary therapy, or in preference to radiotherapy remains controversial.

Citing Articles

Clinical features of pituitary carcinoma: analysis based on a case report and literature review.

Yang Y, Liang W, Fan K, Yang T, Cheng J Front Endocrinol (Lausanne). 2024; 15:1440247.

PMID: 39544231 PMC: 11560426. DOI: 10.3389/fendo.2024.1440247.

Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.

Lin S, Wang L, Han C, Dai Y, Li C, Liu Y Neuro Oncol. 2024; 26(11):2010-2026.

PMID: 38989697 PMC: 11534325. DOI: 10.1093/neuonc/noae130.

Current and Perspective Approaches to the Treatment of Prolactinomas.

Tykhonova T, Barabash N, Kanishcheva O Acta Med Litu. 2024; 30(2):96-107.

PMID: 38516518 PMC: 10952428. DOI: 10.15388/Amed.2023.30.2.1.

Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.

Whyte E, Nezu M, Chik C, Tateno T Endocrinol Metab (Seoul). 2023; 38(6):631-654.

PMID: 37964483 PMC: 10764990. DOI: 10.3803/EnM.2023.1838.

The Role of Aromatase Inhibitors in Male Prolactinoma.

Akirov A, Rudman Y J Clin Med. 2023; 12(4).

PMID: 36835974 PMC: 9962537. DOI: 10.3390/jcm12041437.

References

Quinn J, Jiang S, Reardon D, Desjardins A, Vredenburgh J, Rich J . Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009; 27(8):1262-7. PMC: 2667825. DOI: 10.1200/JCO.2008.18.8417. View

Liu J, Patel J, Eloy J . The role of temozolomide in the treatment of aggressive pituitary tumors. J Clin Neurosci. 2015; 22(6):923-9. DOI: 10.1016/j.jocn.2014.12.007. View

Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K . A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery. 2011; 68(6):E1761-7. DOI: 10.1227/NEU.0b013e318217161a. View

Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H . Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012; 76(6):769-75. DOI: 10.1111/j.1365-2265.2012.04381.x. View

Losa M, Mazza E, Terreni M, McCormack A, Gill A, Motta M . Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol. 2010; 163(6):843-51. DOI: 10.1530/EJE-10-0629. View

Bush Z, Longtine J, Cunningham T, Schiff D, Jane Jr J, Vance M . Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010; 95(11):E280-90. PMC: 5393383. DOI: 10.1210/jc.2010-0441. View

Ieva A, Rotondo F, Syro L, Cusimano M, Kovacs K . Aggressive pituitary adenomas--diagnosis and emerging treatments. Nat Rev Endocrinol. 2014; 10(7):423-35. DOI: 10.1038/nrendo.2014.64. View

Bode H, Seiz M, Lammert A, Brockmann M, Back W, Hammes H . SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes. 2010; 118(10):760-3. DOI: 10.1055/s-0030-1253419. View

McCormack A, Wass J, Grossman A . Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. 2011; 41(10):1133-48. DOI: 10.1111/j.1365-2362.2011.02520.x. View

10.

Nguyen S, Stechishin O, Luchman H, Lun X, Senger D, Robbins S . Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clin Cancer Res. 2014; 20(18):4894-903. DOI: 10.1158/1078-0432.CCR-13-1856. View

11.

Whitelaw B, Dworakowska D, Thomas N, Barazi S, Riordan-Eva P, King A . Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf). 2012; 76(6):877-86. DOI: 10.1111/j.1365-2265.2012.04373.x. View

12.

Mrugala M, Chamberlain M . Mechanisms of disease: temozolomide and glioblastoma--look to the future. Nat Clin Pract Oncol. 2008; 5(8):476-86. DOI: 10.1038/ncponc1155. View

13.

Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L . Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. J Neurooncol. 2015; 122(1):189-96. DOI: 10.1007/s11060-014-1702-0. View

14.

Salehi F, Scheithauer B, Kros J, Lau Q, Fealey M, Erickson D . MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol. 2011; 104(3):647-57. DOI: 10.1007/s11060-011-0532-6. View

15.

Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O . DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab. 2013; 98(3):1130-6. DOI: 10.1210/jc.2012-2924. View

16.

Ortiz L, Syro L, Scheithauer B, Rotondo F, Uribe H, Fadul C . Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo). 2012; 67 Suppl 1:119-23. PMC: 3328813. DOI: 10.6061/clinics/2012(sup01)20. View

17.

Raverot G, Sturm N, De Fraipont F, Muller M, Salenave S, Caron P . Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010; 95(10):4592-9. DOI: 10.1210/jc.2010-0644. View

18.

Losa M, Bogazzi F, Cannavo S, Ceccato F, Curto L, De Marinis L . Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neurooncol. 2015; 126(3):519-25. DOI: 10.1007/s11060-015-1991-y. View

19.

Chatzellis E, Alexandraki K, Androulakis I, Kaltsas G . Aggressive pituitary tumors. Neuroendocrinology. 2015; 101(2):87-104. DOI: 10.1159/000371806. View

20.

Lin A, Sum M, DeAngelis L . Is there a role for early chemotherapy in the management of pituitary adenomas?. Neuro Oncol. 2016; 18(10):1350-6. PMC: 5035521. DOI: 10.1093/neuonc/now059. View